Karuna Therapeutics, Inc.

NasdaqGM:KRTX Voorraadrapport

Marktkapitalisatie: US$12.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Karuna Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Karuna Therapeutics is Bill Meury, benoemd in Jan2023, heeft een ambtstermijn van 1.17 jaar. bezit rechtstreeks 0.027% van de aandelen van het bedrijf, ter waarde $ 3.41M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.1 jaar en 4.3 jaar.

Belangrijke informatie

Bill Meury

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO1.2yrs
Eigendom CEO0.03%
Management gemiddelde ambtstermijn1.1yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

Seeking Alpha • Feb 18

Karuna Therapeutics: Getting Sold Short

Summary Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination. Some shareholders are suing to prevent the acquisition of Karuna by Bristol-Myers Squibb. Also, the vote is outstanding. The 10% or so deal spread seems small. While the chance that the deal falls through would be bad for the short-term performance of Karuna, it may be a buying moment considering the imminent release and size of markets. Read the full article on Seeking Alpha
Seeking Alpha • Sep 09

Karuna Therapeutics: This Ship Has Sailed

Summary Karuna produced excellent data from its phase 3 trial. They have a boatload of cash. Speaking of boats, however, this ship has already sailed. Since my last coverage of Karuna Therapeutics, Inc. (KRTX) just over a year back, the stock has nearly tripled after posting strong results from its schizophrenia trial, meeting the primary endpoint of that trial. That was a month back, and even though the company took the opportunity to carry out a massive $600mn secondary, the dilution hasn’t put a dent in public enthusiasm. The stock is still going strong, although it is back down a few notches. From my previous coverage of the company, they were running a 246-patient phase 3 trial called EMERGENT-2, and 3 more phase 3 trials in the EMERGENT series, in their lead candidate KarXT in acutely psychotic patients with a DSM-5 diagnosis of schizophrenia. KarXT is a differentiated antipsychotic molecule that combines muscarinic-agonist xanomeline and muscarinic-antagonist trospium chloride together. While xanomeline works in the CNS, trospium helps avoid undesirable, cholinergic side effects that arise due to the stimulation of muscarinic receptors in peripheral tissues. The FDA has guided that “data from EMERGENT-1 [a phase 2 study], one successful Phase 3 efficacy and safety trial, and additional safety data to meet regulatory requirements would be acceptable to support NDA filing in schizophrenia.” The first two phase 3 studies were supposed to have toplined in early 2022. In August, the company announced positive data from the EMERGENT-2 trial. This was a double blind, placebo controlled trial done entirely in the United States. It enrolled 252 adult patients with a confirmed diagnosis of schizophrenia who were experiencing symptoms of psychosis. The primary endpoint was change from baseline in Positive and Negative Syndrome Scale ((PANSS)) total score, a scale for measuring schizophrenia symptom severity, of KarXT compared to placebo at Week 5. The trial resoundingly met its primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001). The trial also met key secondary endpoints. Data include: 2.9-point reduction in the PANSS positive subscale with KarXT compared to placebo (-6.8 KarXT vs. -3.9 placebo, p<0.0001). 1.8-point reduction in the PANSS negative subscale with KarXT compared to placebo (-3.4 KarXT vs. -1.6 placebo, p=0.0055). 2.2-point reduction in the PANSS negative Marder factor subscale with KarXT compared to placebo (-4.2 KarXT vs. -2.0 placebo, p=0.0022). The PANSS scores are used to measure positive symptoms (e.g., hallucinations or delusions) and negative symptoms (e.g., difficulty enjoying life or withdrawal from others) of schizophrenia. Benefit in the negative symptoms has historically been difficult to achieve. The trial’s Cohen’s d effect size of 0.61 compares well “to that of widely used and multibillion-dollar blockbusters Risperdal and Zyprexa (about a 0.5 effect size),” according to William Blair analysts. The drug was generally well-tolerated with little differentiation from placebo. There was transient increase in heart rate, which subsided as the trial ended. Importantly, KarXT was not associated with known side effects of current treatments. As FierceBiotech noted: The clinical trial studied KarXT, a xanomeline formulation designed to address the problems that led Lilly to give up on the molecule despite generating evidence of efficacy. Lilly found the M1 agonist improved cognition in Alzheimer’s disease patients in the 1990s, only for tolerability to stop the program. Karuna sought to address the tolerability problems by giving xanomeline with a peripherally restricted molecule that blocks receptors at the root of the issues without crossing the blood-brain barrier to limit efficacy.
Seeking Alpha • Aug 08

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Karuna Therapeutics press release (NASDAQ:KRTX): Q2 GAAP EPS of -$2.17 misses by $0.10. Revenue of $5.28M. The Company ended the quarter with $407.4 million in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as of December 31, 2021. The Company expects that current cash, cash equivalents and available-for-sale investment securities as of June 30, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements for at least 12 months following the potential NDA submission of KarXT for the treatment of psychosis in adults with schizophrenia. Shares +8.29% PM.
Seeking Alpha • Jun 26

Karuna Therapeutics: Front-Running KarXT Phase 3

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event. Despite cash balance issues and new clinical stage competitors, market  indicators suggest that investors are re-engaged.

CEO

Bill Meury (55 yo)

1.2yrs
Tenure

Mr. William Meury, also known as Bill, served as a Partner at Hildred Capital Management LLC. He serves as Director at Crown Laboratories Inc and serves as its Chairman of the Board of Directors. He curren...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Andrew Miller
Founder and President of Research & Developmentno dataUS$5.77m0.037%
$ 4.6m
Stephen Brannan
Chief Medical Officer7yrsUS$4.41m0.095%
$ 11.9m
William Meury
President1.2yrsgeen gegevens0.027%
$ 3.4m
Jason Brown
Chief Financial Officerless than a yeargeen gegevens0.037%
$ 4.6m
Alexis Smith
Vice President of Corporate Affairs & Investor Relationsno datageen gegevensgeen gegevens
Mia Kelley
General Counsel4.2yrsgeen gegevensgeen gegevens
Frank Truslow
Senior Vice President of Corporate Developmentless than a yeargeen gegevensgeen gegevens
Jonathan Rosin
Chief Human Resources Officerless than a yeargeen gegevensgeen gegevens
Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisorno datageen gegevensgeen gegevens
Ronald Marcus
Senior Vice President of Medical3.2yrsgeen gegevensgeen gegevens
William Kane
Chief Commercial Officer1.1yrsgeen gegevens0.013%
$ 1.6m
1.1yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van KRTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
William Meury
President1.2yrsgeen gegevens0.027%
$ 3.4m
Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisorno datageen gegevensgeen gegevens
James Healy
Independent Director4.8yrsUS$336.10k0.085%
$ 10.7m
Jeffrey Jonas
Director5.4yrsUS$326.60k0%
$ 0
Edmund Harrigan
Member of Scientific Advisory Board3.3yrsUS$701.26kgeen gegevens
Christopher Coughlin
Chairman3.9yrsUS$373.15k0%
$ 0
Steven Paul
Director & Member of Scientific Advisory Board6yrsUS$11.22m0.37%
$ 47.0m
Allan Levey
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Atul Pande
Independent Director & Member of Scientific Advisory Board4.8yrsUS$344.60k0%
$ 0
William Potter
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Laurie Olson
Independent Director3.6yrsUS$345.10k0%
$ 0
Richard Keefe
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
4.3yrs
Gemiddelde duur
69yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KRTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/03/18 08:09
Aandelenkoers aan het einde van de dag2024/03/15 00:00
Inkomsten2023/12/31
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Karuna Therapeutics, Inc. wordt gevolgd door 17 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Caroline PalomequeBerenberg
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research